menu ☰
menu ˟

One year of adjuvant trastuzumab remains standard of care for HER2-positive breast cancer

14 Jun 2019
CHICAGO — One year of trastuzumab continues to be the standard of care for adjuvant treatment among patients with early-stage HER2-positive breast cancer, according to the results of a meta-analysis presented at the ASCO Annual Meeting.“There are...

Click here to view the full article which appeared in Hematology Oncology

Please note

The news articles accessible on the Health Well website have been compiled from various sources that are not controlled by the Institute of Public Health in Ireland (IPH). IPH is therefore not responsible for the content of external websites and the inclusion of a link to an external website from the Health Well should not be understood to be an endorsement of that website.